BCL2 and diffuse large B-cell lymphoma: However, in a phase II study CAVALLI of venetoclax plus R-CHOP as first-line treatment for DLBCL, the addition of venetoclax demonstrated improved efficacy, particularly in high-risk BCL-2+ patient subgroup 33.